HR-Positive Metastatic Breast Cancer | Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
Research To Practice | Oncology Videos · Dr. Neil Love
October 25, 202445m 32s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Erika Hamilton, including the following topics:
- Pathophysiology and pharmacology of ER-positive breast cancer treatment (0:00)
- Clinical evidence available with oral selective estrogen receptor degraders (3:46)
- Mechanism of action of proteolysis-targeting chimeras (PROTACs) (13:22)
- PROTACs currently in clinical development (16:39)
- Case: A woman in her late 30s with HR-positive, HER2-negative metastatic breast cancer (mBC) experiencing progression on a CDK4/6 inhibitor (CDK4/6i) and an aromatase inhibitor (AI) (35:09)
- Case: A woman in her early 70s with HR-positive, HER2-negative mBC that progresses on a CDK4/6i and an AI (41:16)